Trademark: 87717852
Status Date
Wednesday, September 8, 2021
Filing Date
Tuesday, December 12, 2017
Abandoned Date
Thursday, August 26, 2021
5 Medical diagnostic reagents for conducting molecular tests; molecular diagnostic reagents for testing of body substances, namely, bone marrow samples, blood samples, and on human or animal tissue, for medical purposes; molecular diagnostic reagents used to test for cancer for medical purposes; medical diagnostic preparations for use in molecular tests using microarray technology and sequencing technology; genetic identity tests comprised of reagents for medical purposes; preparations for detecting genetic predispositions, namely, for measurement of gene aberrations and mutations, for use with clinical multiplex test assays, and for the determination of the genetic sub-type of a patient; reagents for diagnostic medical testing; diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids and tissues in connection with genetic tests, clinical tests, prognostic tests or predictive tests for use in disease detection, namely, hematological disorders; chemical preparations, for medical purposes, for the testing of blood and human or animal tissue for diagnostic purposes
9 Software featuring algorithms for performing diagnostic tests for medical purposes; software for generating and reading out of the genetic properties of a patient sample; software for interpreting and analyzing raw genetic data for use by laboratory users, molecular biologists, pathologists, physicians and patients, for determining the presence of a genetic aberration, mutation, or gene expression profile, genetic subtype of a disease or clinical consequence thereof and prognosis, whether or not in combination with a specific treatment; computer software for operation of a validated, secure IT infrastructure for clinical purposes; downloadable databases featuring anonymous genetic data of patients from clinical studies for comparison with the genetic outcome of patients samples; software operating and user manuals recorded on CDROMs featuring information on diagnostic testing
42 Scientific research and development of molecular diagnostic tests; developing software to perform diagnostic tests for medical purposes; development of software, algorithms and databases for translating, analyzing and interpreting test results; molecular diagnostic analysis for scientific research purposes; research and analysis of bodily tissue and fluids and molecular diagnostic test scores for the purpose of developing new biomarkers, testing, and methods of treatment of diseases and disorders; leasing of computer software for reading test results; development, standardization and validation of molecular diagnostic tests; genetic testing for scientific research purposes
44 Medical analysis services for diagnostic and treatment purposes; analysis of medical and veterinary test scores and data for others for diagnostic and treatment purposes; providing medical and veterinary information; genetic testing for medical purposes; conducting medical tests to determine a patient's prognosis in connection with a disease; providing predictive medical testing for assessing the effectiveness of a medical treatment or to select the medical treatment
Sep 8, 2021
Abandonment Notice E-Mailed - Failure To Respond
Sep 8, 2021
Abandonment - Failure To Respond Or Late Response
Feb 25, 2021
Notification Of Inquiry As To Suspension E-Mailed
Feb 25, 2021
Inquiry To Suspension E-Mailed
Feb 25, 2021
Suspension Inquiry Written
Feb 17, 2021
Assigned To Lie
Jul 29, 2020
Notification Of Letter Of Suspension E-Mailed
Jul 29, 2020
Letter Of Suspension E-Mailed
Jul 29, 2020
Suspension Letter Written
Jul 28, 2020
Teas/Email Correspondence Entered
Jul 28, 2020
Correspondence Received In Law Office
Jul 23, 2020
Teas Response To Suspension Inquiry Received
Jan 27, 2020
Notification Of Inquiry As To Suspension E-Mailed
Jan 27, 2020
Inquiry To Suspension E-Mailed
Jan 27, 2020
Suspension Inquiry Written
Jan 24, 2020
Lie Checked Susp - To Atty For Action
Jul 19, 2019
Notification Of Letter Of Suspension E-Mailed
Jul 19, 2019
Letter Of Suspension E-Mailed
Jul 19, 2019
Suspension Letter Written
Jul 18, 2019
Teas/Email Correspondence Entered
Jul 18, 2019
Correspondence Received In Law Office
Jul 11, 2019
Teas Response To Suspension Inquiry Received
Feb 7, 2019
Notification Of Inquiry As To Suspension E-Mailed
Feb 7, 2019
Inquiry To Suspension E-Mailed
Feb 7, 2019
Suspension Inquiry Written
Feb 6, 2019
Lie Checked Susp - To Atty For Action
Feb 6, 2019
Assigned To Lie
Jul 23, 2018
Notification Of Letter Of Suspension E-Mailed
Jul 23, 2018
Letter Of Suspension E-Mailed
Jul 23, 2018
Suspension Letter Written
Jul 20, 2018
Teas/Email Correspondence Entered
Jul 19, 2018
Correspondence Received In Law Office
Jul 19, 2018
Teas Response To Office Action Received
Mar 30, 2018
Notification Of Non-Final Action E-Mailed
Mar 30, 2018
Non-Final Action E-Mailed
Mar 30, 2018
Non-Final Action Written
Mar 22, 2018
Assigned To Examiner
Dec 22, 2017
New Application Office Supplied Data Entered In Tram
Dec 15, 2017
New Application Entered In Tram
Trademark Alertz updated from USPTO on 2030-01-24
